A Phase 1B Open-Label, Single Ascending Dose Clinical Trial Designed to Evaluate the Safety of Two Dose Levels of Light-activated AU-011 for the Treatment of Subjects With Small to Medium Primary Choroidal Melanoma

Trial Profile

A Phase 1B Open-Label, Single Ascending Dose Clinical Trial Designed to Evaluate the Safety of Two Dose Levels of Light-activated AU-011 for the Treatment of Subjects With Small to Medium Primary Choroidal Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs AU 011 (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions
  • Sponsors Aura Biosciences
  • Most Recent Events

    • 30 Mar 2017 According to an Aura Bioscience media release, the first patient has been enrolled and dosed in this trial.
    • 29 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 07 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top